Pfizer (PFE) Given a $38.00 Price Target by Deutsche Bank Analysts

Deutsche Bank set a $38.00 target price on Pfizer (NYSE:PFE) in a report issued on Wednesday morning. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

A number of other equities research analysts have also recently issued reports on PFE. Berenberg Bank reaffirmed a hold rating and issued a $36.00 target price (down from $39.00) on shares of Pfizer in a report on Tuesday, August 15th. Cowen set a $43.00 target price on shares of Pfizer and gave the company a buy rating in a report on Monday, August 14th. Jefferies Group set a $38.00 target price on shares of Pfizer and gave the company a neutral rating in a report on Monday, October 16th. BMO Capital Markets set a $39.00 target price on shares of Pfizer and gave the company a buy rating in a report on Tuesday, October 31st. Finally, Sanford C. Bernstein set a $39.00 target price on shares of Pfizer and gave the company a buy rating in a report on Tuesday, September 19th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and thirteen have given a buy rating to the stock. The company currently has an average rating of Buy and an average price target of $38.77.

Shares of Pfizer (NYSE PFE) traded down $0.07 during mid-day trading on Wednesday, hitting $35.56. 17,379,200 shares of the stock were exchanged, compared to its average volume of 19,978,311. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.15 and a current ratio of 1.43. The company has a market cap of $212,380.00, a PE ratio of 14.25, a price-to-earnings-growth ratio of 2.51 and a beta of 1.01. Pfizer has a 12 month low of $30.51 and a 12 month high of $36.78.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.02. The company had revenue of $13.17 billion for the quarter, compared to analysts’ expectations of $13.17 billion. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. Pfizer’s quarterly revenue was up .9% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.61 EPS. research analysts anticipate that Pfizer will post 2.59 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Friday, December 1st. Investors of record on Friday, November 10th were paid a $0.32 dividend. The ex-dividend date was Thursday, November 9th. This represents a $1.28 dividend on an annualized basis and a yield of 3.60%. Pfizer’s dividend payout ratio (DPR) is currently 79.01%.

In other Pfizer news, EVP Alexander R. Mackenzie sold 7,350 shares of the stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $35.65, for a total transaction of $262,027.50. Following the transaction, the executive vice president now owns 117,432 shares in the company, valued at approximately $4,186,450.80. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Sally Susman sold 38,230 shares of the stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $35.00, for a total transaction of $1,338,050.00. Following the transaction, the insider now owns 145,649 shares in the company, valued at approximately $5,097,715. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 60,280 shares of company stock worth $2,118,988. Company insiders own 0.06% of the company’s stock.

Several large investors have recently made changes to their positions in the business. Northstar Group Inc. boosted its position in shares of Pfizer by 0.4% during the 2nd quarter. Northstar Group Inc. now owns 8,602 shares of the biopharmaceutical company’s stock worth $289,000 after acquiring an additional 35 shares in the last quarter. Peregrine Asset Advisers Inc. boosted its position in shares of Pfizer by 0.5% during the 2nd quarter. Peregrine Asset Advisers Inc. now owns 7,354 shares of the biopharmaceutical company’s stock worth $247,000 after acquiring an additional 35 shares in the last quarter. Northwest Quadrant Wealth Management LLC boosted its position in shares of Pfizer by 0.8% during the 2nd quarter. Northwest Quadrant Wealth Management LLC now owns 6,329 shares of the biopharmaceutical company’s stock worth $211,000 after acquiring an additional 50 shares in the last quarter. River Wealth Advisors LLC boosted its position in shares of Pfizer by 0.3% during the 2nd quarter. River Wealth Advisors LLC now owns 15,818 shares of the biopharmaceutical company’s stock worth $531,000 after acquiring an additional 55 shares in the last quarter. Finally, Meridian Wealth Management LLC boosted its position in shares of Pfizer by 0.5% during the 2nd quarter. Meridian Wealth Management LLC now owns 11,966 shares of the biopharmaceutical company’s stock worth $402,000 after acquiring an additional 57 shares in the last quarter. Hedge funds and other institutional investors own 69.89% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was first posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this article on another website, it was illegally stolen and reposted in violation of United States and international copyright and trademark law. The correct version of this article can be accessed at https://www.thelincolnianonline.com/2017/12/07/pfizer-pfe-given-a-38-00-price-target-by-deutsche-bank-analysts.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply